TCIM
BIO icon

TIAA CREF Investment Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

TIAA CREF Investment Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$18.9M Sell
61,796
-17,920
-22% -$4.84M 0.01% 729
2018
Q4 		$18.5M Buy
79,716
+2,672
+3% +$717K 0.01% 675
2018
Q3 		$24.1M Sell
77,044
-1,982
-3% -$615K 0.02% 662
2018
Q2 		$22.8M Sell
79,026
-846
-1% -$234K 0.02% 687
2018
Q1 		$20M Sell
79,872
-2,105
-3% -$536K 0.01% 766
2017
Q4 		$19.6M Sell
81,977
-9,896
-11% -$2.4M 0.01% 802
2017
Q3 		$20.4M Buy
91,873
+2,071
+2% +$466K 0.01% 755
2017
Q2 		$20.3M Buy
89,802
+403
+0.5% +$87.8K 0.01% 745
2017
Q1 		$17.8M Sell
89,399
-2,498
-3% -$481K 0.01% 799
2016
Q4 		$16.8M Sell
91,897
-4,408
-5% -$751K 0.01% 829
2016
Q3 		$15.8M Buy
96,305
+6,672
+7% +$1.01M 0.01% 871
2016
Q2 		$12.8M Sell
89,633
-113
-0.1% -$16.1K 0.01% 924
2016
Q1 		$12.3M Buy
89,746
+2,182
+2% +$286K 0.01% 933
2015
Q4 		$12.1M Sell
87,564
-7
-0% -$970 0.01% 966
2015
Q3 		$11.8M Sell
87,571
-1,429
-2% -$206K 0.01% 963
2015
Q2 		$13.4M Buy
89,000
+795
+0.9% +$114K 0.01% 963
2015
Q1 		$11.9M Sell
88,205
-2,574
-3% -$319K 0.01% 1029
2014
Q4 		$10.9M Buy
90,779
+23,015
+34% +$2.65M 0.01% 1057
2014
Q3 		$7.68M Sell
67,764
-361
-0.5% -$42.8K 0.01% 1286
2014
Q2 		$8.15M Sell
68,125
-14,493
-18% -$1.77M 0.01% 1324
2014
Q1 		$10.6M Buy
82,618
+17,490
+27% +$2.24M 0.01% 1100
2013
Q4 		$8.05M Sell
65,128
-1,625
-2% -$198K 0.01% 1295
2013
Q3 		$7.85M Sell
66,753
-3,694
-5% -$436K 0.01% 1248
2013
Q2 		$7.9M Buy
+70,447
New +$8.26M 0.01% 1196

Other funds holding BIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
EIP
Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

TIAA CREF Investment Management's BIO Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Bio-Rad Laboratories Class A (BIO) stake by 22% in Q1 2019, selling an estimated $4.84M and leaving 61,796 shares worth $18.9M. The position accounts for 0.01% of the portfolio, ranked #729.

TIAA CREF Investment Management first reported a position in BIO in Q2 2013 and has held it in 24 quarters since. The position peaked at $24.1M in Q3 2018. 347 funds tracked by Wall St. Rank hold BIO as of Q1 2019.

  • TIAA CREF Investment Management held 61,796 shares of Bio-Rad Laboratories Class A worth $18.9M as of Q1 2019.
  • TIAA CREF Investment Management sold 17,920 Bio-Rad Laboratories Class A shares in Q1 2019, an estimated $4.84M.
  • Bio-Rad Laboratories Class A made up 0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #729 holding.
  • TIAA CREF Investment Management first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Bio-Rad Laboratories Class A position peaked at $24.1M in Q3 2018.
  • 347 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.